<DOC>
	<DOC>NCT02757417</DOC>
	<brief_summary>To determine the safety profile of sodium fluorescein in women undergoing cystoscopy during gynecologic surgery. To determine if either oral phenazopyridine or sodium fluorescein result in shorter cystoscopy times.</brief_summary>
	<brief_title>Intravenous Sodium Fluorescein Versus Oral Phenazopyridine for Ureteral Patency</brief_title>
	<detailed_description />
	<criteria>Patients must be 18 years or older as well as willing and able to provide informed consent Patients undergoing a scheduled gynecologic procedure with cystoscopy Patients are younger than 18 years Patients are unable or unwilling to provide informed consent Patients with a history of an allergic reaction to sodium fluorescein or phenazopyridine Patients with a history of renal insufficiency Patients with a history of liver disease Patients with a history of sickle cell disease Patients with a history of glucose6phosphate dehydrogenase deficiency Patients with a history of chronic obstructive pulmonary disease or currently being treated for asthma</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>